Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shohei Tateishi"'
Autor:
Koji Takano, Miho Yamashita, Akira Shimatsu, Akinobu Nakamura, Atsushi Tominaga, Shingo Fujio, Shigeyuki Tahara, Hiroshi Arima, Hiroshi Nishioka, Shohei Tateishi, Yutaka Takahashi, Yusaku Matsushita, Fumitoshi Satoh
Publikováno v:
Endocrine Journal. 68:791-805
Somatostatin analogs are recommended for pharmacotherapy of TSH-secreting pituitary adenoma (TSHoma). A multicenter clinical trial was conducted to evaluate the efficacy and safety of lanreotide autogel treatment for TSHoma. A total of 13 Japanese pa
Publikováno v:
Progress in Rehabilitation Medicine. 7
Autor:
Akira Shimatsu, Akinobu Nakamura, Yutaka Takahashi, Shingo Fujio, Fumitoshi Satoh, Shigeyuki Tahara, Hiroshi Nishioka, Koji Takano, Miho Yamashita, Hiroshi Arima, Atsushi Tominaga, Shohei Tateishi, Yusaku Matsushita
Publikováno v:
Endocrine Journal; 2021, Vol. 68 Issue 7, p791-805, 15p
Publikováno v:
Computational Statistics & Data Analysis. 59:28-40
In sparse regression modeling via regularization such as the lasso, it is important to select appropriate values of tuning parameters including regularization parameters. The choice of tuning parameters can be viewed as a model selection and evaluati
Autor:
Shohei Tateishi, Sadanori Konishi
Publikováno v:
MI Preprint Series.
We consider the problem of constructing nonlinear regression models in the case that the structure of data has discontinuities at some unknown points. We propose two-stage procedure in which the change points are detected by relevance vector machine
Publikováno v:
MI Preprint Series.
We consider the problem of constructing nonlinear regression models with Gaussian basis functions, using lasso regularization. Regularization with a lasso penalty is an advantageous in that it estimates some coefficients in linear regression models t
Autor:
Doi M; Causal inference working group, data science expert committee, drug evaluation committee, Japan Pharmaceutical Manufacturers Association: Saori Misawa, Masaaki Doi, Yushi Nakanishi, Mikihiro Takamoto, Kazumasa Takenouchi, Shohei Tateishi, Masaru Tsuchikawa, and Daisuke Watanabe.; Clinical Data Science & Quality Management Department, Toray Industries, Inc., Tokyo, Japan., Watanabe D; Causal inference working group, data science expert committee, drug evaluation committee, Japan Pharmaceutical Manufacturers Association: Saori Misawa, Masaaki Doi, Yushi Nakanishi, Mikihiro Takamoto, Kazumasa Takenouchi, Shohei Tateishi, Masaru Tsuchikawa, and Daisuke Watanabe.; Biostatistics, Biostatistics & Programming, Clinical Sciences & Operations, Research & Development, Sanofi K. K., Tokyo, Japan., Takenouchi K; Causal inference working group, data science expert committee, drug evaluation committee, Japan Pharmaceutical Manufacturers Association: Saori Misawa, Masaaki Doi, Yushi Nakanishi, Mikihiro Takamoto, Kazumasa Takenouchi, Shohei Tateishi, Masaru Tsuchikawa, and Daisuke Watanabe.; Biostatistics Group, Data Science, Astellas Pharma Inc., Tokyo, Japan., Tsuchikawa M; Causal inference working group, data science expert committee, drug evaluation committee, Japan Pharmaceutical Manufacturers Association: Saori Misawa, Masaaki Doi, Yushi Nakanishi, Mikihiro Takamoto, Kazumasa Takenouchi, Shohei Tateishi, Masaru Tsuchikawa, and Daisuke Watanabe.; Clinical Administration, Zeria Pharmaceutical Co., Ltd., Tokyo, Japan.
Publikováno v:
Statistics in medicine [Stat Med] 2017 Nov 30; Vol. 36 (27), pp. 4414-4416.